Dex Liquidating (CRDC) 10-Q 9 Nov 17 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document Information [Line Items]
Entity Registrant Name	DEXTERA SURGICAL INC
Entity Central Index Key	1,178,104
Trading Symbol	dxtr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		48,206,226
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 4,180	$ 6,010
Accounts receivable	342	608
Inventories	1,172	1,311
Prepaid expenses and other current assets	158	160
Total current assets	5,852	8,089
Property and equipment, net	574	678
Restricted cash	104	104
Total assets	6,530	8,871
Current liabilities:
Accounts payable	754	929
Accrued compensation	291	487
Other accrued liabilities	667	745
Current portion of deferred revenue	633	633
Current portion of note payable	3,448
Warrant liabilities	6,789	8,638
Total current liabilities	12,582	11,432
Deferred revenue, net of current portion	2,212	2,269
Note payable, net of current portion		3,473
Other non-current liabilities	27	135
Total liabilities	14,821	17,309
Commitments and contingencies (Note 8)
Stockholders' deficit:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; 250,000 shares designated as Series A; 8,000 shares designated as Series B; Convertible preferred stock Series A: 0 shares issued and outstanding at September 30, 2017 and June 30, 2017
Common stock, $0.001 par value: 125,000,000 shares authorized; 48,206,226 and 40,373,240 shares issued and 48,199,604 and 40,366,618 shares outstanding at September 30, 2017 and June 30, 2017, respectively	48	40
Additional paid-in capital	218,716	215,040
Treasury stock at cost (6,622 shares at September 30, 2017 and June 30, 2017)	(596)	(596)
Accumulated other comprehensive loss
Accumulated deficit	(226,459)	(222,922)
Total stockholders' deficit	(8,291)	(8,438)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	6,530	8,871
Series B Preferred Stock [Member]
Current liabilities:
Redeemable convertible preferred stock Series B: 172 and 273 shares issued and outstanding at September 30, 2017 and June 30, 2017, respectively

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2017	Jun. 30, 2017
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	48,206,226	40,373,240
Common stock, shares outstanding (in shares)	48,199,604	40,366,618
Treasury stock, shares acquired (in shares)	6,622	6,622
Series B Preferred Stock [Member]
Redeemable convertible preferred stock, shares issued (in shares)	172	273
Redeemable convertible preferred stock, shares outstanding (in shares)	172	273
Preferred stock, shares authorized (in shares)	8,000	8,000
Preferred stock, shares outstanding (in shares)	172
Series A Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	250,000	250,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net revenue:
Product sales, net	$ 572,000	$ 427,000
License and development revenue	105,000	26,000
Royalty revenue	17,000	14,000
Total net revenue	694,000	467,000
Operating costs and expenses:
Cost of product sales	951,000	515,000
Research and development	1,748,000	1,768,000
Selling, general and administrative	1,824,000	2,019,000
Total operating costs and expenses	4,523,000	4,302,000
Loss from operations	(3,829,000)	(3,835,000)
Interest income	1,000	14,000
Interest expense	(150,000)	(133,000)
Other income (expense), net	441,000	(1,000)
Net loss	(3,537,000)	(3,955,000)
Deemed dividend attributable to convertible preferred stock	(101,000)
Net loss allocable to common stockholders	$ (3,638,000)	$ (3,955,000)
Basic net loss per share allocable to common stockholders (in dollars per share)	$ (0.09)	$ (0.44)
Diluted net loss per share allocable to common stockholders (in dollars per share)	$ (0.09)	$ (0.44)
Shares used in computing basic net loss per share allocable to common stockholders (in shares)	42,660	8,928
Shares used in computing diluted net loss per share allocable to common stockholders (in shares)	45,199	8,928

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net loss	$ (3,537)	$ (3,955)
Other comprehensive gain (loss):
Change in unrealized loss on investments, net of tax
Comprehensive loss	$ (3,537)	$ (3,955)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - 3 months ended Sep. 30, 2017 - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Jun. 30, 2017	273	40,373,240
Balance at Jun. 30, 2017	$ 0	$ 40	$ 215,040	$ (596)	$ 0	$ (222,922)	$ (8,438)
Deemed dividend related to accretion of discounts upon conversion of convertible preferred stock Series B	$ 101		(101)				(101)
Conversion of convertible preferred stock Series B for common shares (in shares)	(101)	374,074
Conversion of convertible preferred stock Series B for common shares	$ (101)		101				101
Common stock issued upon exercise of common stock warrants: Cash proceeds (in shares)		7,387,584
Common stock issued upon exercise of common stock warrants: Cash proceeds		$ 8	1,987				1,995
Common stock issued upon exercise of common stock warrants: Warrant liability at time of exercise			1,391				1,391
Common stock issued under the 2016 ESPP (in shares)		71,328
Common stock issued under the 2016 ESPP			16				16
Stock-based compensation expense			282				282
Net loss						(3,537)	(3,537)
Balance (in shares) at Sep. 30, 2017	172	48,206,226
Balance at Sep. 30, 2017	$ 0	$ 48	$ 218,716	$ (596)	$ 0	$ (226,459)	$ (8,291)

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net loss	$ (3,537)	$ (3,955)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	120	160
Amortization of premiums on marketable securities		9
Remeasurement of common stock warrant liability	(458)
Stock-based compensation	282	299
Non-cash interest expense	100	83
Changes in assets and liabilities:
Accounts receivable	266	(136)
Prepaid expenses and other current assets	2	119
Inventories	139	(230)
Accounts payable and other accrued liabilities	(361)	(4)
Accrued compensation	(196)	(28)
Deferred revenue	(57)	(26)
Net cash used in operating activities	(3,700)	(3,709)
Investing activities:
Purchases of property and equipment	(16)	(26)
Proceeds from maturities of investments		4,000
Purchases of investments		(596)
Net cash provided by (used in) investing activities	(16)	3,378
Financing activities:
Repayment of principal on note payable	(125)
Proceeds from issuance of common stock under ESPP	16
Proceeds from the exercise of common stock warrants	1,995
Net cash provided by financing activities	1,886
Net decrease in cash and cash equivalents	(1,830)	(331)
Cash and cash equivalents at beginning of period	6,010	3,626
Cash and cash equivalents at end of period	4,180	3,295
Supplemental disclosure of cash flow information:
Cash paid for interest	50	50
Conversion of Series B Preferred Stock to Common Stock [Member]
Supplemental disclosure of non-cash investing and financing information:
Convertible preferred stock Series B converted to common stock	101
Series B Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing information:
Deemed dividend attributable to convertible preferred stock	$ 101

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Organization Dextera Surgical Inc. (the “Company”) was incorporated in the state of Delaware on October 15, 1997, November 26, 2001, June 19, 2016, 5/80™ 30 5/80™ 5 80 30 45, 8 45 30, first 30, 5/80. In March 2012, 30 30” 30, not 5/80 December 2012, 30 510 30 January 2014, February 2014, 30 30 March 2014, first 30 November 2014, ’ feedback. In April 2015, 30 November 2015, 30 30 5/80 30. 5/80, 510 January 2016, 510 5/80 July 2016, 510 5/80 5/80 510 5/80, 5/80. Historically, the Company generated product revenues primarily from the sale of automated anastomotic systems; however, the Company started generating revenues from the commercial sales of the MicroCutter products since its introduction in Europe in December 2012, March 2014, September 30, 2017, $3.1 For the three September 30, 2017, $0.7 0.4 $0.2 $0.1 $17,000 Going Concern The Company has incurred cumulative net losses of $226.5 September 30, 2017, September 30, 2017, $4.2 $3.9 The Company believes that the existing cash and cash equivalents will be sufficient to meet its anticipated cash needs to enable it to conduct its business substantially as currently conducted at least through the end of December 2017. may To satisfy its short-term and longer-term liquidity requirements, the Company may third one may may not may may The Company ’s condensed consolidated financial statements have been prepared assuming that it will continue as a going concern. This assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Its continuations as a going concern is contingent upon its ability to raise financing. However, there can be no not Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not not The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended June 30, 2017, 10 October 13, 2017. Recently Issued Accounting Standards In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017 11 , Earnings Per Share (Topic 260 480 815 N oncontrolling Interests with a Scope Exception. no 2017 11 2017 11 December 15, 2018, 2020 July 1, 2019). not In May 2017, the FASB issued ASU 2017 09, Compensation-Stock Compensation (Topic 718 2017 09 2017 09 December 15, 2017, 2019 July 1, 2018). not In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 December 15, 2017, 2019 July 1, 2018). not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, December 15, 2019, 2021 July 1, 2020). In February 2016, No. 2016 02, Leases (Topic 842 September 2017, 842. 842 12 December 15, 2018, 2020 July 1, 2019). not In January 2016, 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01 December 15, 2017, 2019 July 1, 2018). In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 605 , Revenue Recognition March, April, May December 2016, September 2017, 606. 606 606 may 606 December 15, 2017, 2019 July 1, 2018), Use of Estimates The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Significant estimates include the valuation of inventory, measurement of stock-based compensation, valuation of warrant liability and revenue recognition. Actual results could materially differ from these estimates. Revenue Recognition The Company recognizes revenue when four 1 2 3 4 third not The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not ’s sales to distributors do not Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not Inventories Inventories are recorded at the lower of cost or market on a first first may Risks and Uncertainties The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company ’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not not none Foreign Currency Translation The Company ’s foreign operations are subject to exchange rate fluctuations and foreign currency costs. The functional currency of the German subsidiary is the United States dollar. Transactions and balances denominated in dollars are presented at their original amounts. Monetary assets and liabilities denominated in currencies other than the dollar are re-measured at the current exchange rate prevailing at the balance sheet date. All transaction gains or losses from the re-measurement of monetary assets and liabilities are included in the consolidated statements of operations within other income (expense).

Note 2 - Stockholders' Deficit

Note 2 - Stockholders' Deficit	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 2 DEFICIT Preferred Stock Financing Arrangement The Company has 5,000,000 one The Company designated 250,000 191,474 April 2014. three June 30, 2017, 191,474 1,914,740 In May 2017, 8,000 May 16, 2017, 8,000 $1,000 $8 $1.3 Through June 30, 2017, 7,727 28,618,487 ’s common stock. During the three September 30, 2017, 101 374,074 172 September 30, 2017. three September 30, 2017, $0.1 Because convertible preferred stock Series B can be redeemed by holders upon a change in control that could occur outside the Company ’s control, it is classified in the Company’s consolidated balance sheets as a separate line item outside permanent stockholders’ deficit (“mezzanine”). Accretion of preferred stock to its redemption value is not September 30, 2017, not not . Stock-Based Compensation Stock-based compensation expense related to employee and director share-based compensation plans, including stock options and restricted stock units, or RSUs, pursuant to ASC 718 , Compensation — Stock Compensation 505 50, Equity Based Payments to Non-Employees In September 2016, ’s board of directors approved the adoption of the 2016 “2016 November 2016. 2016 300,000 first 2016 March 16, 2017, five August 15, 2017 six February 15, 2018. 2016 one two six first 2016 August 16 th February 16 th 2016 one two six 2016 not 2016 2016 423 1986 85% first six three September 30, 2017, 2016 71,328 $22,000, The Company selected the Black-Scholes option pricing model for determining the estimated fair value-based measurements of share-based awards. The use of the Black-Scholes model requires the use of assumptions including expected term, expected volatility, risk-free interest rate and expected dividends. The Company used the following assumptions in its fair value-based measurements: Stock Option Plan: Three months ended September 30, 2017 2016 Risk-free interest rate 1.9 % 1.1 % Dividend yield — — Weighted-average expected life (in years) 4.8 4.8 Expected volatility 96 % 75 % Employee Stock Purchase Plan: Three months ended September 30, 2017 Risk-free interest rate 1.1% Dividend yield — Weighted-average expected life (in years) 0.5 - 1.0 Expected volatility 143% - 171% The Company estimates the expected life of options granted based on historical exercise and post-vest cancellation patterns, which the Company believes are representative of future behavior. The risk-free interest rate for the expected term of each option is based on a risk-free zero not ’s historical stock price. The Company estimates forfeitures in calculating the expense related to stock-based compensation. The Company recorded stock-based compensation expenses for awards granted to employees under ASC 718 $0.3 three September 30, 2017 2016. not 505 50 three September 30, 2017 2016, not $0.4 September 30, 2017, 3.6 Included in the statement of operations are the following non-cash stock-based compensation expenses (in thousands): Three months ended September 30, 2017 2016 Cost of product sales $ 37 $ 23 Research and development 73 68 Selling, general and administrative 172 208 Total $ 282 $ 299

Note 3 - Net Loss Per Share

Note 3 - Net Loss Per Share	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 3 Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period without consideration of potential shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive potential common share equivalents outstanding for the period less the dilutive potential shares of common stock for the period determined using the treasury-stock method . The calculation of diluted loss per share also requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrant liabilities, and the presumed exercise of such securities is dilutive to earnings (loss) per share for the period, adjustments to net income or net loss used in the calculation are required to remove the change in fair value of the warrants for the period. Likewise, adjustments to the denominator are required to reflect the related dilutive shares. For purposes of this calculation, options, warrants and convertible preferred shares to purchase stock and unvested restricted stock awards are considered to be potential shares of common stock and are only included in the calculation of diluted net loss per share when their effect is dilutive. In the years the Preferred Stock was outstanding, the two 260 Earnings per Share two two two no not The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share data): Three Months Ended September 30, 2017 2016 Numerator: Net loss $ (3,537 ) $ (3,955 ) Deemed dividend attributable to convertible preferred stock (101 ) - Net loss allocable to common stockholders - basic $ (3,638 ) $ (3,955 ) Adjustment for revaluation of warrant liabilities (458 ) - Net loss allocable to common stockholders - diluted $ (4,096 ) $ (3,955 ) Denominator: Weighted average number of common shares outstanding – basic 42,660 8,928 Dilutive securities: Common stock warrants 2,539 - Weighted average number of common shares outstanding – diluted 45,199 8,928 Net loss allocable to common stockholders - basic $ (0.09 ) $ (0.44 ) Net loss allocable to common stockholders - diluted $ (0.09 ) $ (0.44 ) The following table sets forth the outstanding securities not September 30, 201 7 2016, As of September 30, 2017 2016 Options to purchase common stock 1,501 1,488 Unvested restricted stock awards 174 27 Shares reserved for issuance upon conversion of convertible Series A and Series B 374 1,915 2,049 3,430

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 4 – FAIR VALUE MEASUREMENTS ASC 820, 820 three three Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than quoted prices included in Level 1, not Level 3 Unobservable inputs that are supported by little or no All assets and liabilities measured at fair value on a recurring basis have been segregated into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. Assets and liabilities measured at fair value are summarized below (in thousands): As of September 30, 2017 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 280 $ — $ — $ 280 Total assets at fair value $ 280 $ — $ — $ 280 Financial liabilities: Warrant liabilities $ — $ — $ 6,789 $ 6,789 Total liabilities at fair value $ — $ — $ 6,789 $ 6,789 As of June 30, 2017 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 280 $ — $ — $ 280 Total assets at fair value $ 280 $ — $ — $ 280 Financial liabilities: Warrant liabilities $ — $ — $ 8,638 $ 8,638 Total liabilities at fair value $ — $ — $ 8,638 $ 8,638 Funds held in money market instruments, are included in Level 1 Level 3 consist of common stock warrant liabilities. In aggregate, during the May 2017 2 1 29,632,000 2 14,816,000 $0.27 1 fifth 2 first 1 2 The following table sets forth a summary of the changes in the estimated fair value of common stock warrant liabilities which were measured at fair value on a recurring basis (in thousands): Balances as of June 30, 2017 $ 8,638 Gain from remeasurement (458 ) Exercises into common stock (1,391 ) Balance as of September 30, 2017 $ 6,789 The fair values of the outstanding common stock warrants are measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value include the estimated fair value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and estimated volatility. The Company used the following assumptions in its fair value-based measurements: September 30, June 30, 2017 Risk-free interest rate 1.2% – 1.9% 1.2% – 1.9% Dividend yield — — Remaining contractual term (in years) 0.6 – 4.6 0.9 – 4.9 Volatility 96% – 158% 94% – 141% The remaining contractual term of the warrants is used as the expected life of the warrants. The risk-free interest rate is based on a risk-free zero not ’s historical stock price and is determined based on the remaining contractual term of the warrants. Gain from remeasurement was included in other income (expense), net. During the three September 30, 2017, 1 81,489 2 7,306,095 $2.0 September 30, 2017, 1 29,487,545 2 6,667,311 Corporate debt securities and commercial papers are valued primarily using market prices comparable securities, bid/ask quotes, interest rate yields, and prepayment spreads and are included in Level 2. Cash ba lances of $3.9 September 30, 2017, $5.7 June 30, 2017, not September 30, 2017, September 30, 2017, 3

Note 5 - Inventories

Note 5 - Inventories	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	N OTE 5 – INVENTORIES Inventories consisted of the following (in thousands): September 30, 2017 June 30, 2017 Raw materials $ 657 $ 757 Work in progress 166 171 Finished goods 349 383 Total $ 1,172 $ 1,311

Note 6 - Distribution, License,

Note 6 - Distribution, License, Development and Commercialization Agreements	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 6 – DISTRIBUTION, LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTS Century On September 2, 2011, ’s planned MicroCutter products in Japan. Under the terms of a secured note purchase agreement, Century agreed to loan the Company an aggregate of up to $4.0 September 30, 2016, two July 1, 2014. $2.0 September 30, 2011, $2.0 December 27, 2011. 5% 7 In return for the loan commitment, the Company granted Century distribution rights to the Company ’s planned MicroCutter product line in Japan, and a right of first August 2013, 30 April 2014, 30 third 2014 January 2015, August 2015, 30 5/80 5/80 Proceeds from the note and granting the distribution rights were allocated to the note based on its aggregate fair value of $2.4 18%, $1.6 first not September 30, 2017. The Company ’s distribution agreement with Century pertaining to the PAS-Port system, originally dated June 16, 2003, July 31, 2014. September 30, 2018, July 1, 2014, five July 31, 2019. 2011 $3.1 $2.6 $0.5 18%, $0.5 first For the three September 30, 2017 2016, 11% 16%, September 30, 2017 June 30, 2017, 19% 28%, Intuitive Surgical On August 16, 2010, ’s intellectual property in the robotics field in diagnostic or therapeutic medical procedures, but excluding vascular anastomosis applications, for an upfront license fee of $9.0 The Company determined that there were two August 16, 2010, may three $9.0 $1.0 were aggregated and allocated to the two $9.0 $10.0 August 16, 2010, June 30, 2011, $1.0 may three three June 30, 2014. On December 31, 2015, August 2010, ’s da Vinci one $2.0 August 16, 2018, December 31, 2015, June 30, 2016. may The feasibility evaluation allowed Intuitive Surgical to test and evaluate the Company ’s MicroCutter technology. The six 8 da Vinci November 2017, not The Company determined that there were two December 30, 2015; may two $2.0 two 3 $1.4 $2.0 December 30, 2015 three March 31, 2016, $0.6 may two two As of September 30, 2017, $1.7 September 30, 2017, $0.3 September 30, 2017, $0.1 Cook Incorporated In June 2007, September 2007 June 2009 The Company’s significant deliverables under the arrangement were the license rights and the associated development activities. These deliverables were determined to represent one no not three September 30, 2017 2016. not $0.4 September 30, 2017 June 30, 2017. January 6, 2010, not

Note 7 - Note Payable

Note 7 - Note Payable	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 7 – NOTE PAYABLE In connection with the Distribution Agreement with Century (see Note 6 $4.0 June 30, 2012, July 1, 2014, two $2.0 September 30, 2011, $2.0 December 27, 2011. 5% September 30, 2018. $2.1 no In August 2016, ’s loan in the amount of $4.0 ten $44.0 April 2014, July 2014 September 30, 2018. 7% not April 2014 In September 2017, 1 $125,000 September 30, 2017, December 31, 2017, March 31, 2018, June 30, 2018; ( 2 ’s allegation that the earlier payment was due, and ( 3 no $3.5 September 30, 2018. As of September 30, 2017 June 30, 2017, $3.4 $3.5 $0.4 $0.5

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8 – COMMITMENTS AND CONTINGENCIES Operating Lease On November 11, 2010, four August 31, 2015, 0.1 June 30, 2012. November 24, 2014, three September 1, 2015, August 31, 2018 ( three August 31, 2018 ( $0.1 September 30, 2017 June 30, 2017, Future minimum lease payments under the Company ’s non-cancelable operating leases having initial terms of a year or more as of September 30, 2017, Operating Fiscal year ending June 30, Leases 2018 (remaining nine months) $ 777 2019 173 Total $ 950

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Organization [Policy Text Block]	Organization Dextera Surgical Inc. (the “Company”) was incorporated in the state of Delaware on October 15, 1997, November 26, 2001, June 19, 2016, 5/80™ 30 5/80™ 5 80 30 45, 8 45 30, first 30, 5/80. In March 2012, 30 30” 30, not 5/80 December 2012, 30 510 30 January 2014, February 2014, 30 30 March 2014, first 30 November 2014, ’ feedback. In April 2015, 30 November 2015, 30 30 5/80 30. 5/80, 510 January 2016, 510 5/80 July 2016, 510 5/80 5/80 510 5/80, 5/80. Historically, the Company generated product revenues primarily from the sale of automated anastomotic systems; however, the Company started generating revenues from the commercial sales of the MicroCutter products since its introduction in Europe in December 2012, March 2014, September 30, 2017, $3.1 For the three September 30, 2017, $0.7 0.4 $0.2 $0.1 $17,000
Liquidity [Policy Text Block]	Going Concern The Company has incurred cumulative net losses of $226.5 September 30, 2017, September 30, 2017, $4.2 $3.9 The Company believes that the existing cash and cash equivalents will be sufficient to meet its anticipated cash needs to enable it to conduct its business substantially as currently conducted at least through the end of December 2017. may To satisfy its short-term and longer-term liquidity requirements, the Company may third one may may not may may The Company ’s condensed consolidated financial statements have been prepared assuming that it will continue as a going concern. This assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Its continuations as a going concern is contingent upon its ability to raise financing. However, there can be no not
Basis of Presentation and Principles of Consolidation [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not not The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended June 30, 2017, 10 October 13, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017 11 , Earnings Per Share (Topic 260 480 815 N oncontrolling Interests with a Scope Exception. no 2017 11 2017 11 December 15, 2018, 2020 July 1, 2019). not In May 2017, the FASB issued ASU 2017 09, Compensation-Stock Compensation (Topic 718 2017 09 2017 09 December 15, 2017, 2019 July 1, 2018). not In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 December 15, 2017, 2019 July 1, 2018). not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 December 15, 2019, December 15, 2019, 2021 July 1, 2020). In February 2016, No. 2016 02, Leases (Topic 842 September 2017, 842. 842 12 December 15, 2018, 2020 July 1, 2019). not In January 2016, 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01 December 15, 2017, 2019 July 1, 2018). In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 605 , Revenue Recognition March, April, May December 2016, September 2017, 606. 606 606 may 606 December 15, 2017, 2019 July 1, 2018),
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Significant estimates include the valuation of inventory, measurement of stock-based compensation, valuation of warrant liability and revenue recognition. Actual results could materially differ from these estimates.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue when four 1 2 3 4 third not The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not ’s sales to distributors do not Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not
Inventory, Policy [Policy Text Block]	Inventories Inventories are recorded at the lower of cost or market on a first first may
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Risks and Uncertainties The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company ’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not not none
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company ’s foreign operations are subject to exchange rate fluctuations and foreign currency costs. The functional currency of the German subsidiary is the United States dollar. Transactions and balances denominated in dollars are presented at their original amounts. Monetary assets and liabilities denominated in currencies other than the dollar are re-measured at the current exchange rate prevailing at the balance sheet date. All transaction gains or losses from the re-measurement of monetary assets and liabilities are included in the consolidated statements of operations within other income (expense).

Note 2 - Stockholders' Deficit

Note 2 - Stockholders' Deficit (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three months ended September 30, 2017 2016 Risk-free interest rate 1.9 % 1.1 % Dividend yield — — Weighted-average expected life (in years) 4.8 4.8 Expected volatility 96 % 75 %
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three months ended September 30, 2017 Risk-free interest rate 1.1% Dividend yield — Weighted-average expected life (in years) 0.5 - 1.0 Expected volatility 143% - 171%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three months ended September 30, 2017 2016 Cost of product sales $ 37 $ 23 Research and development 73 68 Selling, general and administrative 172 208 Total $ 282 $ 299

Note 3 - Net Loss Per Share (Ta

Note 3 - Net Loss Per Share (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, 2017 2016 Numerator: Net loss $ (3,537 ) $ (3,955 ) Deemed dividend attributable to convertible preferred stock (101 ) - Net loss allocable to common stockholders - basic $ (3,638 ) $ (3,955 ) Adjustment for revaluation of warrant liabilities (458 ) - Net loss allocable to common stockholders - diluted $ (4,096 ) $ (3,955 ) Denominator: Weighted average number of common shares outstanding – basic 42,660 8,928 Dilutive securities: Common stock warrants 2,539 - Weighted average number of common shares outstanding – diluted 45,199 8,928 Net loss allocable to common stockholders - basic $ (0.09 ) $ (0.44 ) Net loss allocable to common stockholders - diluted $ (0.09 ) $ (0.44 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of September 30, 2017 2016 Options to purchase common stock 1,501 1,488 Unvested restricted stock awards 174 27 Shares reserved for issuance upon conversion of convertible Series A and Series B 374 1,915 2,049 3,430

Note 4 - Fair Value Measureme19

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of September 30, 2017 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 280 $ — $ — $ 280 Total assets at fair value $ 280 $ — $ — $ 280 Financial liabilities: Warrant liabilities $ — $ — $ 6,789 $ 6,789 Total liabilities at fair value $ — $ — $ 6,789 $ 6,789 As of June 30, 2017 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents: Money market funds $ 280 $ — $ — $ 280 Total assets at fair value $ 280 $ — $ — $ 280 Financial liabilities: Warrant liabilities $ — $ — $ 8,638 $ 8,638 Total liabilities at fair value $ — $ — $ 8,638 $ 8,638
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Balances as of June 30, 2017 $ 8,638 Gain from remeasurement (458 ) Exercises into common stock (1,391 ) Balance as of September 30, 2017 $ 6,789
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	September 30, June 30, 2017 Risk-free interest rate 1.2% – 1.9% 1.2% – 1.9% Dividend yield — — Remaining contractual term (in years) 0.6 – 4.6 0.9 – 4.9 Volatility 96% – 158% 94% – 141%

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2017 June 30, 2017 Raw materials $ 657 $ 757 Work in progress 166 171 Finished goods 349 383 Total $ 1,172 $ 1,311

Note 8 - Commitments and Cont21

Note 8 - Commitments and Contingencies (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Operating Fiscal year ending June 30, Leases 2018 (remaining nine months) $ 777 2019 173 Total $ 950

Note 1 - Summary of Significa22

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		58 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Jun. 30, 2017
Revenue, Net	$ 694,000	$ 467,000
License and Services Revenue	105,000	26,000
Royalty Revenue	17,000	$ 14,000
Retained Earnings (Accumulated Deficit)	(226,459,000)		$ (226,459,000)	$ (222,922,000)
Cash, Cash Equivalents, and Short-term Investments	4,200,000		4,200,000
Long-term Debt, Gross	$ 3,900,000		3,900,000
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Microcutter Products [Member]
Revenue, Net	$ 200,000		$ 3,100,000
Automated Anastomotic Systems [Member]
Revenue, Net	$ 400,000

Note 2 - Stockholders' Defici23

Note 2 - Stockholders' Deficit (Details Textual)	May 16, 2017USD ($)$ / sharesshares	Mar. 16, 2017	Apr. 30, 2014shares	Sep. 30, 2017USD ($)shares	Jun. 30, 2017shares	Sep. 30, 2016USD ($)	Jun. 30, 2017shares	Mar. 31, 2017shares
Preferred Stock, Shares Authorized				5,000,000	5,000,000		5,000,000
Number of Votes				1
Allocated Share-based Compensation Expense | $				$ 300,000		$ 300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $				$ 400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				3 years 219 days
Non-employees [Member]
Allocated Share-based Compensation Expense | $				$ 0		0
The 2016 Employee Stock Purchase Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance								300,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		85.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans				71,328
Allocated Share-based Compensation Expense | $				$ 22,000
Conversion of Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted					191,474
Conversion of Stock, Shares Issued					1,914,740
Conversion of Series B Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted				101			7,727
Conversion of Stock, Shares Issued				374,074			28,618,487
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized				250,000	250,000		250,000
Stock Issued During Period, Shares, New Issues			191,474
Preferred Stock, Shares Outstanding				0	0		0
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized	8,000			8,000	8,000		8,000
Stock Issued During Period, Shares, New Issues	8,000
Sale of Stock, Price Per Share | $ / shares	$ 1,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants | $	$ 8,000,000
Payments of Stock Issuance Costs | $	$ 1,300,000
Preferred Stock, Shares Outstanding				172
Conversion of Stock, Deemed Dividend | $				$ 101,000

Note 2 - Stockholders' Defici24

Note 2 - Stockholders' Deficit - Black-scholes Valuation Assumptions (Details)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Risk-free interest rate	1.90%	1.10%
Dividend yield		0.00%
Weighted-average expected life (in years) (Year)	4 years 292 days	4 years 292 days
Expected volatility	96.00%	75.00%

Note 2 - Stockholders' Defici25

Note 2 - Stockholders' Deficit - Employee Stock Purchase Plan Valuation Assumptions (Details)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Risk-free interest rate	1.90%	1.10%
Dividend yield		0.00%
Weighted-average expected life (in years) (Year)	4 years 292 days	4 years 292 days
Expected volatility	96.00%	75.00%
The 2016 Employee Stock Purchase Plan [Member]
Risk-free interest rate	1.10%
Dividend yield	0.00%
The 2016 Employee Stock Purchase Plan [Member] | Minimum [Member]
Weighted-average expected life (in years) (Year)	182 days
Expected volatility	143.00%
The 2016 Employee Stock Purchase Plan [Member] | Maximum [Member]
Weighted-average expected life (in years) (Year)	1 year
Expected volatility	171.00%

Note 2 - Stockholders' Defici26

Note 2 - Stockholders' Deficit - Non-cash Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation expense	$ 282	$ 299
Cost of Sales [Member]
Stock-based compensation expense	37	23
Research and Development Expense [Member]
Stock-based compensation expense	73	68
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 172	$ 208

Note 3 - Net Loss Per Share - C

Note 3 - Net Loss Per Share - Computation of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net loss	$ (3,537)	$ (3,955)
Deemed dividend attributable to convertible preferred stock	(101)
Net loss allocable to common stockholders - basic	(3,638)	(3,955)
Adjustment for revaluation of warrant liabilities	(458)
Net loss allocable to common stockholders - diluted	$ (4,096)	$ (3,955)
Denominator:
Shares used in computing basic net loss per share allocable to common stockholders (in shares)	42,660	8,928
Common stock warrants (in shares)	2,539
Weighted average number of common shares outstanding – diluted (in shares)	45,199	8,928
Basic net loss per share allocable to common stockholders (in dollars per share)	$ (0.09)	$ (0.44)
Diluted net loss per share allocable to common stockholders (in dollars per share)	$ (0.09)	$ (0.44)

Note 3 - Net Loss Per Share - A

Note 3 - Net Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive securities excluded from the computation of earnings per share (in shares)	2,049	3,430
Employee Stock Option [Member]
Antidilutive securities excluded from the computation of earnings per share (in shares)	1,501	1,488
Restricted Stock [Member]
Antidilutive securities excluded from the computation of earnings per share (in shares)	174	27
Common Stock Shares Reserved for Future Issuance [Member]
Antidilutive securities excluded from the computation of earnings per share (in shares)	374	1,915

Note 4 - Fair Value Measureme29

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	May 16, 2017
Proceeds from Warrant Exercises	$ 1,995
Cash	$ 3,900		$ 5,700
Series 1 Warrants Issued in Connection with Preferred Stock Series B [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	29,487,545			29,632,000
Class of Warrant or Right, Exercised During Period	81,489
Series 2 Warrants Issued in Connection with Preferred Stock Series B [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,667,311			14,816,000
Class of Warrant or Right, Exercised During Period	7,306,095
Series 1 and 2 Warrants Issued in Connection with Preferred Stock Series B [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.27
Proceeds from Warrant Exercises	$ 2,000

Note 4 - Fair Value Measureme30

Note 4 - Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Total assets at fair value	$ 280	$ 280
Warrant liabilities	6,789	8,638
Total liabilities at fair value	6,789	8,638
Fair Value, Inputs, Level 1 [Member]
Total assets at fair value	280	280
Warrant liabilities
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Total assets at fair value
Warrant liabilities
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Total assets at fair value
Warrant liabilities	6,789	8,638
Total liabilities at fair value	6,789	8,638
Money Market Funds [Member]
Cash equivalents	280	280
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	280	280
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents

Note 4 - Fair Value Measureme31

Note 4 - Fair Value Measurements - Fair Value of Common Stock Warrant Liabilities (Details) - Warrant Liability [Member] $ in Thousands	3 Months Ended
	Sep. 30, 2017USD ($)
Balance	$ 8,638
Gain from remeasurement	(458)
Exercises into common stock	(1,391)
Balance	$ 6,789

Note 4 - Fair Value Measureme32

Note 4 - Fair Value Measurements - Warrant Liability Valuation Assumption (Details) - Warrant Liability [Member]	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Minimum [Member]
Risk-free interest rate	1.20%	1.20%
Dividend yield
Remaining contractual term (in years) (Year)	219 days	328 days
Volatility	96.00%	94.00%
Maximum [Member]
Risk-free interest rate	1.90%	1.90%
Dividend yield
Remaining contractual term (in years) (Year)	4 years 219 days	4 years 328 days
Volatility	158.00%	141.00%

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Raw materials	$ 657	$ 757
Work in progress	166	171
Finished goods	349	383
Total	$ 1,172	$ 1,311

Note 6 - Distribution, Licens34

Note 6 - Distribution, License, Development and Commercialization Agreements (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 30, 2015	Jul. 01, 2014	Dec. 27, 2011	Sep. 30, 2011	Sep. 02, 2011	Aug. 16, 2010	Sep. 30, 2011	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Aug. 31, 2016	Jun. 30, 2012	Jun. 30, 2011
Deferred Revenue, Noncurrent									$ 2,212,000			$ 2,269,000
Deferred Revenue, Current									$ 633,000			$ 633,000
Century Medical [Member] | Product Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage									11.00%	16.00%
Century Medical [Member] | Product Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage									19.00%			28.00%
Intuitive Surgical [Member] | Initial Licensing Agreement [Member]
Licenses Revenue							$ 9,000,000
Common Stock Premium							1,000,000
Noncash or Part Noncash Divestiture, Amount of Consideration Received							$ 10,000,000
Deferred Revenue, Noncurrent															$ 1,000,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member]
Licenses Revenue									$ 1,700,000
Proceeds from License Fees Received	$ 2,000,000
Deferred Revenue, Current									300,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member] | Patented Technology [Member]
Proceeds from License Fees Received		$ 1,400,000
Intuitive Surgical [Member] | Amended Licensing Agreement [Member] | Developed Technology Rights [Member]
Proceeds from License Fees Received											$ 600,000
Intuitive Surgical [Member] | Joint Development Program [Member]
Licenses Revenue									100,000
Cook Incorporated [Member]
Licenses Revenue									0	$ 0
Deferred Revenue, Current									$ 400,000			$ 400,000
Century Medical [Member]
Debt Instrument, Face Amount													$ 4,000,000
Proceeds from Secured Notes Payable				$ 2,000,000	$ 2,000,000			$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage									5.00%
Notes Payable, Fair Value Disclosure			$ 2,600,000			$ 2,400,000
Debt Instrument, Unamortized Discount			$ 2,100,000
Distribution Agreement Term of Extension			5 years
Notes Payable			$ 3,100,000
Century Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount						$ 4,000,000								$ 4,000,000
Debt Instrument, Interest Rate, Stated Percentage						5.00%
Fair Value Inputs, Discount Rate			18.00%			18.00%
Debt Instrument, Unamortized Discount			$ 500,000			$ 1,600,000
Deferred Revenue			$ 500,000

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - USD ($)	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 27, 2011	Sep. 30, 2011	Apr. 30, 2014	Sep. 30, 2011	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Aug. 31, 2016	Jul. 01, 2014	Jun. 30, 2012	Sep. 02, 2011
Proceeds from Issuance or Sale of Equity								$ 44,000,000
Repayments of Long-term Debt										$ 125,000
Notes Payable, Noncurrent												$ 3,473,000
Century Medical [Member]
Debt Instrument, Face Amount													$ 4,000,000
Proceeds from Secured Notes Payable						$ 2,000,000	$ 2,000,000		$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage					5.00%					5.00%
Debt Instrument, Unamortized Discount														$ 2,100,000
Repayments of Long-term Debt					$ 125,000
Century Medical [Member] | Pro Forma [Member]
Debt Instrument, Penalty Rate					7.00%					7.00%
Century Medical [Member] | Scenario, Forecast [Member]
Repayments of Long-term Debt	$ 3,500,000	$ 125,000	$ 125,000	$ 125,000
Century Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount															$ 4,000,000	$ 4,000,000
Debt Instrument, Interest Rate, Stated Percentage																5.00%
Debt Instrument, Unamortized Discount														$ 500,000		$ 1,600,000
Notes Payable, Noncurrent					$ 3,400,000					$ 3,400,000		3,500,000
Debt Issuance Costs, Line of Credit Arrangements, Net					$ 400,000					$ 400,000		$ 500,000

Note 8 - Commitments and Cont36

Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017	Aug. 31, 2015
Leasehold Improvements, Gross			$ 100
Restricted Cash and Cash Equivalents	$ 104	$ 104
Restricted Cash, Letter of Credit [Member]
Restricted Cash and Cash Equivalents	$ 100	$ 100

Note 8 - Commitments and Cont37

Note 8 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2017USD ($)
2018 (remaining nine months)	$ 777
2,019	173
Total	$ 950